Name (required):

  Expression ^{(Optional mood/title along with your name) Examples: (happy, sad, The Joyful, etc.) help)}

  E-mail address (optional):

* Type your message here:
>Rituxin (from IDPH) > was the first FDA approved drug for cancer (in the >US) utilizing monoclonal antibodies. This could have >important significance to AVN if they developed it >using "monomouse" technology. AVN who owns 100% of the >patent equally with IDPH has stated that they have a >verbal agreement with IDPH to commercialize "monomice" >technology. If brought to the market, "monomouse" >technology may compete with ABGX's "xenomouse" and >MEDX's "humabmouse". Both ABGX and MEDX became high >flying stocks this year based on the mouse technology. >AVN, which still sells for less than $4 per share, >feels that their technology is superior to that of >ABGX and MEDX. AVN has stated that they will announce >plans to commercialize "monomouse" technology within >30-60 days or > sooner. AVN has also recently been approved for the >first over the counter herpes cream using n-docosanol. >The product > will be marketed by SBH upon final labeling approval. >In addition, AVN has the exciting IgE technology in >the pipeline which may help bring relief someday to >millions of allergy sufferers. The possibility of >developing IgE and monoclonal antibodies could make a >perfect combination. This puts AVN in company with >Genentech (DNA) who have similiar technology using >humanized antibodies. > > http://biz.yahoo.com/p/a/avn.html > > http://www.avanir.com/

Notice: Copies of your message may remain on this and other systems on internet. Please be respectful.